Recurrent/Relapsed Rectal Cancer

Aspirin May Prolong Life in PIK3CA-Mutated Colorectal Cancers (11-6-2012)

Daily aspirin use improves survival among patients with mutated-PIK3CA colorectal cancer, according to the results of a study published in the New England Journal of Medicine. Colorectal cancer remains the second leading cause of cancer-related death... Continue Reading

Zaltrap Approved for Metastatic Colorectal Cancer (08-15-2012)

The U.S. Food and Drug Administration (FDA) has approved Zaltrap® (ziv-aflibercept) for use in combination with the FOLFIRI chemotherapy regimen (folinic acid, fluorouracil, and ironotecan) to treat adults with metastatic colorectal cancer. Colorectal... Continue Reading

Regorafenib Shows Promise Against Metastatic Colorectal Cancer (01-19-2012)

The investigational drug regorafenib improves survival and delays cancer progression among patients with metastatic colorectal cancer that has worsened in spite of other treatments. These results will be presented at the 2012 Gastrointestinal Cancers... Continue Reading

Study Evaluates Whole-brain Radiation Following Surgery or Radiosurgery in Cancer Spread to the Brain (11-16-2010)

Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival or duration of functional independence but does... Continue Reading

Study Takes Closer Look at Erbitux Efficacy in Patients with Specific KRAS Mutations (11-8-2010)

Although colorectal cancer patients with mutations in the KRAS gene tend not to respond to drugs such as Erbitux® (cetuximab), responsiveness may vary by the specific type of KRAS mutation. These results were published in the Journal of the American... Continue Reading

Radioembolization plus Fluorouracil Active in Colorectal Cancer Patients with Liver Metastases (07-2-2010)

Radioembolization plus the chemotherapy agent fluorouracil slows cancer progression for colorectal cancer patients whose disease has progressed following prior treatment with chemotherapy and have metastases limited to the liver. These findings were recently... Continue Reading

Preventive Treatment Reduces Skin Side Effects of Vectibix (02-16-2010)

Among patients with metastatic colorectal cancer treated with the targeted therapy Vectibix® (panitumumab), preventive skin care reduces the occurrence of skin side effects. These results were published in the Journal of Clinical Oncology. Colorectal... Continue Reading

Vectibix Improves Outcome of Previously Treated Colorectal Cancer (01-27-2010)

Among patients with previously treated, metastatic colorectal cancer, the addition of the targeted therapy Vectibix® (panitumumab) to chemotherapy delayed cancer progression. This benefit was only observed in patients whose tumors did not contain... Continue Reading

Hemoglobin Level Among Factors that May Predict Outcome in Rectal Cancer (03-8-2009)

Hemoglobin Level Among Factors that May Predict Outcome in Rectal Cancer Researchers in the United States have recently published results indicating that certain prognostic factors may predict outcome for patients undergoing radiation for locally recurrent... Continue Reading

Early Skin Treatment Reduces Skin Reactions in Colorectal Cancer Patients Treated with Vectibix® (03-8-2009)

Early Skin Treatment Reduces Skin Reactions in Colorectal Cancer Patients Treated with Vectibix® Among patients with colorectal cancer, skin treatment beginning on the day prior to therapy with Vectibix® (panitumumab) significantly reduces skin side... Continue Reading

« Previous PageNext Page »